Search - tctmd.com

Displaying 1 - 20 of 72

Sort: Relevancy | Date

Presentation TVT 2023

What do the New Trials Need to Show In Light of PROTECTED-TAVR

Presenter: Amit Vora

June 09, 2023

Presentation TVT 2023

Novel CEP Devices: Progress in Aortic Arch Deflector Devices

Presenter: Azeem Latib

June 09, 2023

Presentation TVT 2023

Novel New CEP Devices: Progress in Debris Capture and Removal

Presenter: Tamim Nazif

June 09, 2023

Presentation TVT 2023

Position 2: The Trial Was Obviously Negative: Stop Wasting Money!

Presenter: David Cohen

June 09, 2023

Presentation TVT 2023

Has the Dust Settled After PROTECTED TAVR? Flash Review of the Results and What Will We Learn From the BHF-TAVI Study

Presenter: Samir Kapadia

June 09, 2023

Presentation TVT 2023

Stroke after TAVR: To Protect or Not to Protect?

Presenter: John Forrest

June 08, 2023

Presentation TVT 2023

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

Presenter: Tamim Nazif

June 07, 2023

Presentation TVT 2022

Pharmacologic "Protection" to Reduce Strokes After TAVR: Current Evidence and Recommendations

Presenter: George Dangas

June 10, 2022

Presentation TVT 2022

LAAO for Atrial Fibrillation After TAVR: The Other Elephant In The Room

Presenter: Amar Krishnaswamy

June 10, 2022

Presentation TVT 2022

Clinical Trial Pathways and Study Designs: Embolic Capture vs Deflection Devices

Presenter: Alexandra Lansky

June 10, 2022

Presentation TVT 2022

Novel Embolic Protection Technologies: The Current State of Play

Presenter: Giora Weisz

June 10, 2022

Presentation TVT 2022

Stroke Prevention With Sentinel: Update From PROTECTED TAVR and BHF PROTECT-TAVI

Presenter: Samir Kapadia

June 10, 2022

Presentation TVT 2022

Percutaneous Debulking of a Mitral Valve Mass in a Patient Presenting with Recurrent Stroke

Presenter: Nahyr Lugo-Fagundo

June 09, 2022

Presentation TVT 2022

Cerebral Embolic Protection and Severity of Stroke Following Transcatheter Aortic Valve Replacement

Presenter: Toshiaki Isogai

June 09, 2022

Presentation TVT 2022

Percutaneous Debulking of a Mitral Valve Mass in a Patient Presenting With Recurrent Stroke

Presenter: Nahyr Lugo-Fagundo

June 09, 2022

Presentation TVT 2021

PFO Closure in Non-Stroke Patients

Presenter: Brian Whisenant

July 22, 2021

Presentation TVT 2021

PFO Closure for Stroke: When Should We Consider Patients Over 60 Years of Age?

Presenter: Megan Coylewright

July 22, 2021

Presentation TVT 2021

When Both Silent AF and PFO Are Discovered During a Cryptogenic Stroke Work-up, the Optimal Therapy to Prevent Stroke Recurrence Is…

Presenter: Mark Reisman

July 22, 2021

Presentation TVT 2021

Next Generation Stroke Reduction

Presenter: Wayne Batchelor

July 21, 2021

Presentation TVT 2021

Does Medical Therapy Make a Difference: Anti-Platelet and Anti-Thrombotic Therapy After TAVR

Presenter: George Dangas

July 21, 2021

Advertisement

What do the New Trials Need to Show In Light of PROTECTED-TAVR

Novel CEP Devices: Progress in Aortic Arch Deflector Devices

Novel New CEP Devices: Progress in Debris Capture and Removal

Position 2: The Trial Was Obviously Negative: Stop Wasting Money!

Has the Dust Settled After PROTECTED TAVR? Flash Review of the Results and What Will We Learn From the BHF-TAVI Study

Stroke after TAVR: To Protect or Not to Protect?

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

Pharmacologic "Protection" to Reduce Strokes After TAVR: Current Evidence and Recommendations

LAAO for Atrial Fibrillation After TAVR: The Other Elephant In The Room

Clinical Trial Pathways and Study Designs: Embolic Capture vs Deflection Devices

Novel Embolic Protection Technologies: The Current State of Play

Stroke Prevention With Sentinel: Update From PROTECTED TAVR and BHF PROTECT-TAVI

Percutaneous Debulking of a Mitral Valve Mass in a Patient Presenting with Recurrent Stroke

Cerebral Embolic Protection and Severity of Stroke Following Transcatheter Aortic Valve Replacement

Percutaneous Debulking of a Mitral Valve Mass in a Patient Presenting With Recurrent Stroke

PFO Closure in Non-Stroke Patients

PFO Closure for Stroke: When Should We Consider Patients Over 60 Years of Age?

When Both Silent AF and PFO Are Discovered During a Cryptogenic Stroke Work-up, the Optimal Therapy to Prevent Stroke Recurrence Is…

Next Generation Stroke Reduction

Does Medical Therapy Make a Difference: Anti-Platelet and Anti-Thrombotic Therapy After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content